Insider Trading Alert - MACK, CASH And NCMI Traded By Insiders

Yesterday, March 2, 2016, 118 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $267.02 to $8,394,878.24.

Highlighted Stocks Traded by Insiders:

Merrimack Pharmaceuticals (MACK) - FREE Research Report

Porter Michael E, who is Director at Merrimack Pharmaceuticals, bought 20,000 shares at $6.11 on March 2, 2016. Following this transaction, the Director owned 719,448 shares meaning that the stake was boosted by 2.86% with the 20,000-share transaction.

The shares most recently traded at $6.50, up $0.39, or 6.08% since the insider transaction. Historical insider transactions for Merrimack Pharmaceuticals go as follows:

  • 4-Week # shares bought: 37,000
  • 12-Week # shares bought: 37,000
  • 24-Week # shares bought: 37,000

The average volume for Merrimack Pharmaceuticals has been 1.6 million shares per day over the past 30 days. Merrimack Pharmaceuticals has a market cap of $753.5 million and is part of the health care sector and drugs industry. Shares are down 13.73% year-to-date as of the close of trading on Wednesday.

Merrimack Pharmaceuticals, Inc., a biopharmaceutical company, engages in discovering, developing, and preparing to commercialize medicines paired with companion diagnostics for the treatment of cancer primarily in the United States. Currently, there are 3 analysts who rate Merrimack Pharmaceuticals a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on MACK - FREE

TheStreet Quant Ratings rates Merrimack Pharmaceuticals as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, generally disappointing historical performance in the stock itself and feeble growth in its earnings per share. Get the full Merrimack Pharmaceuticals Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Meta Financial Group (CASH) - FREE Research Report

Moore Frederick V, who is Director at Meta Financial Group, sold 550 shares at $41.90 on March 2, 2016. Following this transaction, the Director owned 100 shares meaning that the stake was reduced by 84.62% with the 550-share transaction.

The shares most recently traded at $41.67, down $0.23, or 0.55% since the insider transaction. Historical insider transactions for Meta Financial Group go as follows:

  • 4-Week # shares bought: 1,000
  • 4-Week # shares sold: 500
  • 12-Week # shares bought: 1,000
  • 12-Week # shares sold: 500
  • 24-Week # shares bought: 1,000
  • 24-Week # shares sold: 500

The average volume for Meta Financial Group has been 42,000 shares per day over the past 30 days. Meta Financial Group has a market cap of $356.8 million and is part of the financial sector and banking industry. Shares are down 8.71% year-to-date as of the close of trading on Wednesday.

Meta Financial Group, Inc. operates as the holding company for MetaBank that offers various banking products and services to individuals, small businesses, financial institutions, and other businesses. The stock currently has a dividend yield of 1.24%. The company has a P/E ratio of 16.2. Currently, there are 2 analysts who rate Meta Financial Group a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on CASH - FREE

TheStreet Quant Ratings rates Meta Financial Group as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, increase in net income, expanding profit margins and solid stock price performance. We feel its strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Meta Financial Group Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

National CineMedia (NCMI) - FREE Research Report

Schneider Scott N, who is Director at National CineMedia, sold 13,500 shares at $15.19 on March 2, 2016. Following this transaction, the Director owned 59,633 shares meaning that the stake was reduced by 18.46% with the 13,500-share transaction.

The shares most recently traded at $14.79, down $0.40, or 2.7% since the insider transaction. Historical insider transactions for National CineMedia go as follows:

  • 4-Week # shares sold: 45,452
  • 12-Week # shares sold: 45,452
  • 24-Week # shares sold: 45,452

The average volume for National CineMedia has been 292,100 shares per day over the past 30 days. National CineMedia has a market cap of $973.1 million and is part of the services sector and media industry. Shares are down 4.87% year-to-date as of the close of trading on Wednesday.

National CineMedia, Inc., together with its subsidiaries, operates a digital in-theatre media network in North America. The stock currently has a dividend yield of 5.67%. The company has a P/E ratio of 59.6. Currently, there are 7 analysts who rate National CineMedia a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on NCMI - FREE

TheStreet Quant Ratings rates National CineMedia as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, increase in net income and expanding profit margins. However, as a counter to these strengths, we find that the growth in the company's earnings per share has not been good. Get the full National CineMedia Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

More from Markets

Why Jim Cramer Isn't Surprised By the Jobs Report

Why Jim Cramer Isn't Surprised By the Jobs Report

What to Expect From the Markets in 2019 According to an Abbott Downing Executive

What to Expect From the Markets in 2019 According to an Abbott Downing Executive

Illinois Tool Works Stock Falls Despite In-Line Earnings Guidance

Illinois Tool Works Stock Falls Despite In-Line Earnings Guidance

Dow Falls For Third Day, Loses 4.4% in Week on Jobs Report, Trade Fears

Dow Falls For Third Day, Loses 4.4% in Week on Jobs Report, Trade Fears

Rates Are 'About Right,' Says Federal Reserve's Bullard

Rates Are 'About Right,' Says Federal Reserve's Bullard